News for Tonix Pharmaceuticals Hld Stock (TNXP)

Tonix Pharmaceuticals Plans Massachusetts R&D Facility to Accelerate Clinical Development of Vaccines and Protein-Based Therapeutics

GlobeNewsWire • 07/07/20

Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule

GlobeNewsWire • 06/29/20

Tonix Pharmaceuticals Announces Results from Preclinical Study of TNX-1700 Presented in a Poster at AACR Virtual Annual Meeting 2020

GlobeNewsWire • 06/22/20

Tonix Pharmaceuticals and Southern Research Announce Expansion of COVID-19 Vaccine Collaboration

GlobeNewsWire • 06/18/20

Tonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020

GlobeNewsWire • 06/17/20

Tonix Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of License

GlobeNewsWire • 06/11/20

Tonix Pharmaceuticals Announces Appointment of Richard H. Bagger to Board of Directors

GlobeNewsWire • 06/10/20

Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800

GlobeNewsWire • 06/01/20

Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical Psychopharmacology

GlobeNewsWire • 05/21/20

Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine

GlobeNewsWire • 05/19/20

Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights

GlobeNewsWire • 05/12/20

Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia

GlobeNewsWire • 04/24/20

Tonix Pharmaceuticals to Deliver Virtual Presentation and Participate in Panel Discussion for Planet MicroCap Showcase Virtual Investor Conference 2020

GlobeNewsWire • 04/20/20

Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering

GlobeNewsWire • 03/03/20

Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market

GlobeNewsWire • 02/28/20

Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering

GlobeNewsWire • 02/11/20

Tonix Pharmaceuticals Prices $7.5 million Public Offering

GlobeNewsWire • 02/07/20

Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD

GlobeNewsWire • 02/05/20

Tonix Pharmaceuticals Moves Ahead, And Other News: The Good, Bad, And Ugly Of Biopharma

Seeking Alpha • 01/30/20

Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference

GlobeNewsWire • 01/29/20

Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL

GlobeNewsWire • 01/24/20

Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study

GlobeNewsWire • 12/16/19

Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL

GlobeNewsWire • 12/11/19

Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

GlobeNewsWire • 12/10/19

Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD

GlobeNewsWire • 11/26/19